Form 4: Plus Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Richard J. Hawkins acquired stock options in Plus Therapeutics, Inc. on September 11, 2024.
Summary
- Richard J. Hawkins, a director of Plus Therapeutics, Inc. (PSTV), filed a Form 4 on September 12, 2024, reporting a transaction.
- On September 11, 2024, Hawkins acquired 3,650 stock options with an exercise price of $1.26.
- These options vest monthly over 12 months from the grant date or in full at the next annual meeting, contingent on continued service.
- Following the transaction, Hawkins directly owns 3,650 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reports a standard transaction. The acquisition of options by a director is generally viewed as a slightly positive signal.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC filing related to insider transactions, common in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the stock option transaction. |
| 09/12/2024 | Date the Form 4 was signed. |
| 09/11/2034 | Expiration date of the stock options. |
Keywords
Form 4, stock options, derivative securities, beneficial ownership, Plus Therapeutics, Hawkins, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.